Comparison of Disease Related Health Care Resource Utilization (HRU) and Costs in Chronic Obstructive Pulmonary Disease (COPD) Patients Receiving Nebulized Long-Acting β2-Agonists (LABAs)

Yaozhu Chen; Charles Maken; Vamsi Bollu

首页> 外文期刊>Chest >Comparison of Disease Related Health Care Resource Utilization (HRU) and Costs in Chronic Obstructive Pulmonary Disease (COPD) Patients Receiving Nebulized Long-Acting β2-Agonists (LABAs)

【24h】

Comparison of Disease Related Health Care Resource Utilization (HRU) and Costs in Chronic Obstructive Pulmonary Disease (COPD) Patients Receiving Nebulized Long-Acting β2-Agonists (LABAs)

机译：接受雾化长效β2-激动剂（LABA）的慢性阻塞性肺疾病（COPD）患者的疾病相关医疗资源利用（HRU）和费用的比较

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Chest》 |2014年第4期|共页
作者
Yaozhu Chen; Charles Maken; Vamsi Bollu;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类呼吸系及胸部疾病;
关键词

相似文献

外文文献
中文文献
专利

1. ADDITIONAL EFFECT OF INHALED CORTICO STEROID (ICS) ON PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE RECEIVING LONG-ACTING MUSCARINIC ANTAGONIST(LAMA)/ LONG-ACTING beta 2-AGONIST(LABA) - SINGLE-CENTRE, PROSPECTIVE, REAL-WORLD STUDY [J] . Tanaka Yosuke, Yajima Chika, Hino Mitsunori, Respirology : . 2017,第Suppla3期

机译：吸入的Cortico类固醇（ICS）对慢性阻塞性肺病患者接受长效毒蕈碱拮抗剂（喇嘛）/长效β2-激动剂（LABA）的额外效果 - 单中心，前瞻性，真实的研究
2. Healthcare Resource Utilization, Exacerbations, and Readmissions Among Medicare Patients with Chronic Obstructive Pulmonary Disease After Long-Acting Muscarinic Antagonist Therapy Initiation with Soft Mist versus Dry Powder Inhalers [J] . David Singer, Lindsay GS Bengtson, Caitlin Elliott, International Journal of Chronic Obstructive Pulmonary Disease . 2020,第1期

机译：医疗保健资源利用率，慢性阻塞性肺病患者的慢性阻塞性肺病患者中的再服用，用软雾与干粉吸入器
3. Differences in the efficacy and safety among inhaled corticosteroids (ICS)/long-acting beta2-agonists (LABA) combinations in the treatment of chronic obstructive pulmonary disease (COPD): Role of ICS [J] . Latorre M., Novelli F., Vagaggini B., Pulmonary pharmacology & therapeutics . 2015,第Null期

机译：吸入性糖皮质激素（ICS）/长效β2-激动剂（LABA）组合在治疗慢性阻塞性肺疾病（COPD）中的功效和安全性差异：ICS的作用
4. Telehomecare Technologies Enhance Self-management and Empowerment among Patients with Chronic Obstructive Pulmonary Disease (COPD) - Where does Health Literacy Fit into this Equation? [C] . Lisa Korsbakke Emtekaer Haesum, Lars Ehlers, Ole K Hejlesen MEDINFO . 2013

机译：Telehomecare Technologies提高慢性阻塞性肺病（COPD）患者的自我管理和赋权 - 健康识字在哪里适合这种方程式？
5. Hospital resource utilization among patients with chronic obstructive pulmonary disease—An analysis of 2002–2005 Healthcare Cost and Utilization Project data [D] . Rane, Pallavi B. 2010

机译：慢性阻塞性肺疾病患者的医院资源利用——2002-2005年医疗费用与利用项目数据分析
6. Exacerbations Health Resource Utilization and Costs Among Medicare Beneficiaries with Chronic Obstructive Pulmonary Disease Treated with Nebulized Arformoterol Following a Respiratory Event [O] . Maryam Navaie, Bartolome R. Celli, Zhun Xu, 2019

机译：呼吸事件后雾化阿福特罗治疗慢性阻塞性肺疾病的医疗保险受益人的病情加重卫生资源利用和费用
7. PRS1 Characteristics of Patients with Chronic Obstructive Pulmonary Disease (COPD) Receiving Inhaled Corticosteroid/Long-Acting b2-ß2-agonist (ICS/LABA) Fixed Combination Products in English Primary Care [O] . Blak B.T., Rigney U., Emmas C., 2013

机译：慢性阻塞性肺疾病（COPD）患者在英国初级护理中接受吸入糖皮质激素/长效b2-ß2-激动剂（ICS / LABA）固定组合产品的PRS1特征

Comparison of Disease Related Health Care Resource Utilization (HRU) and Costs in Chronic Obstructive Pulmonary Disease (COPD) Patients Receiving Nebulized Long-Acting β2-Agonists (LABAs)

著录项

相似文献

相关主题

期刊订阅